Tat strongly stimulates transcription of the human immunodeficiency type 1 (HIV-1) provirus by interacting with various cellular transcription factors, including TFIID. The results presented in this report indicate that the effect exerted by Tat also involves an interaction with TFIIB. A direct protein-protein interaction between Tat and TFIIB was observed in vitro. Detailed analysis of this interaction showed that the cysteine-rich and core domains of Tat bind to the N-terminal moiety of the general transcription factor. The role of the interaction between Tat and TFIIB in the activation of the entire HIV-1 promoter was analysed. Transfection experiments performed using a reporter construct containing the HIV-1 long terminal repeat fused to a reporter gene showed that overexpression of TFIIB progressively suppressed Tat-induced transcription. This effect was weakened by an increase in the intracellular con-
Introduction
The transactivator Tat plays a crucial role in the life cycle of human immunodeficiency virus type 1 (HIV-1), as well as in the pathology induced by this virus in humans. It is now established that in infected patients HIV-1 replicates actively (Ho et al., 1995 ; Wei et al., 1995) and that Tat intervenes in this process by strongly inducing transcription of the integrated provirus. However, the molecular mechanisms that permit this small viral protein to subvert the cellular transcriptional machinery to the benefit of the virus remain to be elucidated in detail. It is known that Tat activates the HIV-1 promoter via the TAR element located downstream of the initiation site (for a review see Jones, 1993) , as well as via the upstream promoter sequences which correspond to binding sites for the cellular Author for correspondence : Pierre Jalinot. transcription factors Sp1 and NF-κB Berkhout et al., 1990 ; Taylor et al., 1992) . TAR is active as RNA (Selby et al., 1990 ; Southgate et al., 1990) and Tat binds to this sequence (Dingwall et al., 1989) , probably in combination with cellular factors (Jones, 1993) . The role played by the Sp1 and NF-κB binding sites in Tat transactivation is probably due to the binding of this transactivator to cellular proteins interacting with these motifs (Jeang et al., 1993 ; Taylor et al., 1995) . Thus it would appear that Tat binds to various sites near the formation of the transcriptional initiation complex on the core promoter elements. Tat increases the number of RNA polymerase II molecules initiating transcription, as well as the stability of the transcriptional elongation complex (Laspia et al., 1989) . This latter effect has been observed during in vitro transcription experiments and depends on a specific cellular activity (Kato et al., 1992 ; Marciniak et al., 1990 ; Zhou & Sharp, 1995) . Stimulation of the initiation rate probably results from influencing the general transcription factors forming the transcriptional initiation complex. Kashanchi et al. (1994) have shown that Tat interacts with TFIID in vitro via its core factor TBP and we have previously reported on the diverse evidence indicating that Tat\TBP interaction plays a functional role in vivo (Veschambre et al., 1995) .
Another known target for transcriptional activators is the general transcription factor TFIIB, which allows recruitment of the RNA polymerase II associated with TFIIF. We show in this report that Tat also binds to TFIIB. Various mutants of Tat and TFIIB have allowed a precise mapping of the domains of both proteins involved in the interaction. Transient expression experiments performed both with a reporter plasmid possessing the HIV-1 promoter fused to the CAT gene and with a HeLa cell line bearing the HIV-1 promoter fused to the lacZ gene in its genome, showed that large amounts of TFIIB suppressed the Tat-induced transcription. The inhibitory capacity of TFIIB mutants unable to enter the transcriptional initiation complex was correlated to their ability to bind to Tat. Mutants of TFIIB which were functional for basal transcription, but which did not bind to Tat, exhibited a dominant negative effect.
We conclude from these results that Tat, by interacting with the general transcription factors TBP and TFIIB, stabilizes the complex that they form on the TATA box in an active conformation, which results in a high transcriptional initiation rate.
Methods
Plasmids and transfection assays. Construction of the vectors expressing Tat, GBTat, TBP and TFIIB has been described previously (Veschambre et al., 1995) . All these vectors are derivatives of pSG5. pSG-TFIIB ∆67-80, ∆83-103, ∆148-163 and ∆208-227 were obtained by inserting the NdeI-BamHI restriction fragment of the pET vectors, allowing expression in bacteria of the corresponding TFIIB mutants (Hisatake et al., 1993) between the EcoRI and BamHI restriction sites of pSG5. The NdeI and EcoRI restriction sites were filled-in prior to ligation. Construction of the reporter constructs pG6RGCAT (Veschambre et al., 1995) and pHIV-1 long terminal repeat (LTR) CAT (Emerman et al., 1987) , as well as establishment of the P4 cell line (kindly provided by P. Charneau through the courtesy of J.-L. Darlix ; Clavel & Charneau, 1994) , have been described previously. HeLa cells were transfected by the calcium phosphate co-precipitation method. The amounts of plasmids used in the different transfections are indicated in the legends to the figures. The total amount of SV40 promoter-containing constructs was adjusted to a constant level with pSG5. The total amount of transfected DNA was adjusted to 15 µg with pUC plasmid. Transfections were done without an internal control (Farr & Roman, 1992) , but were repeated with at least two different plasmid preparations. Each transfection was done in duplicate, and the values given correspond to the mean of the two measurements. The concentration of CAT enzyme was measured using an ELISA (Boehringer Mannheim) and the β-galactosidase activity was determined by performing a colorimetric assay using the β-galactosidase Enzyme Assay System (Promega).
Protein-protein interactions. Production in bacteria of the GST-Tat and GST-TFIIB fusion proteins, as well as the in vitro binding assay, was performed as previously described (Veschambre et al., 1995) . For these in vitro binding assays, Tat and TFIIB were produced and labelled with [$&S]methionine using the TT Coupled Reticulocyte Lysate System (Promega) with plasmids pSG-Tat, pSG-TFIIB and the derivatives of the pET vector expressing the series of mutants of TFIIB scanning the entire protein (Hisatake et al., 1993) . The in vitro binding assay was also performed with TFIIB produced in E. coli and purified by chromatography (Moncollin et al., 1992) . The presence of specific proteins in the gel was analysed either by autoradiography or by immunoblotting using the monoclonal antibody 2G8 directed against TFIIB (Moncollin et al., 1992) .
Results

Cooperative effect of TBP and TFIIB on transcription activated by DNA-bound Tat
When it artificially binds to DNA as a fusion protein with the DNA binding domain of GAL4 (protein GBTat), Tat can activate transcription in the absence of TAR. This activity requires the presence of binding sites for other transcriptional activators, such as Sp1 or USF, in the promoter of the reporter construct (Southgate & Green, 1991) . In a previous study we showed that overexpression of TBP induces the activity of GBTat, which was observed in the absence of other transcriptional activators (Veschambre et al., 1995) . In this study it was observed that coexpression of the general transcription factor TFIIB has an inhibitory effect.
To investigate this point more precisely, we evaluated the effect of increasing intracellular concentrations of TFIIB on the activity of GBTat, in the presence of a constant amount of TBP. This experiment was performed using the pG6RGCAT reporter construct which contains six binding sites for GAL4 upstream of the HIV-1 TATA box fused to the gene coding for CAT (Fig. 1 E) . This plasmid was cotransfected with vectors expressing TBP and GBTat, together with various amounts of one expressing the human form of TFIIB. The experiment was performed using two different amounts of the vector expressing GBTat (150 and 75 ng). Low amounts of TFIIB clearly increased the activity of GBTat observed in the presence of overexpressed TBP (Fig. 1 A, B) . In contrast, higher amounts of this general transcription factor reduced this activity. Interestingly, the transition between activation and suppression for 150 ng of transfected pSG-GBTat was observed with an amount of pSG-TFIIB which was twice that required for 75 ng of transfected pSG-GBTat, suggesting a direct interaction between GBTat and TFIIB. It was verified by immunoblotting experiments that this inhibition was not due to a decrease in the amounts of GBTat and TBP proteins when TFIIB was coexpressed ( Fig. 1 C, D) .
The cysteine-rich and core domains of Tat allow direct binding to TFIIB In order to investigate a possible direct interaction between TFIIB and Tat, the Tat protein was purified from bacteria as a fusion protein with glutathione S-transferase (GST-Tat). A clear interaction was observed of TFIIB (produced in bacteria This plasmid includes six binding sites for GAL4 upstream of the HIV-1 TATA element from position k36 to k6 with respect to the initiation site of the viral RNA. These promoter elements were fused to the sequence coding for chloramphenicol acetyltransferase (CAT).
and purified by chromatography ; Moncollin et al., 1992) with GST-Tat, whereas no retention of this factor was observed on beads coupled to GST (Fig. 2 A) . As both proteins used in this experiment were highly purified, this result indicates that the interaction was direct and did not depend on a bridging factor. The reverse experiment was also performed. Tat was produced and radioactively labelled by in vitro translation, and its retention on beads coupled to GST-IIB was analysed. A clear binding of Tat to immobilized TFIIB was observed (Fig. 2 B) . These results demonstrate that Tat and TFIIB interact in vitro.
In order to delineate the domains of Tat permitting this interaction, several Tat mutants were tested using this in vitro binding assay. Deletion of the basic domain did not impair the interaction of Tat with TFIIB (Fig. 3, lane 3 ). An additional deletion of the first nine amino acid residues led to a slight increase in the amount of TFIIB retained on the beads (Fig. 3 , lane 4). Deletion of both the N-terminal nine-amino-acid domain and the C-terminal moiety from amino acid residue 49 did not significantly modify the retention of TFIIB, as compared to that observed with wild-type Tat (Fig. 3 , lanes 2 and 1). In contrast, substitution of cysteine-30 and lysine-41 for glycine clearly impaired the binding of TFIIB to Tat (Fig. 3 , lanes 5 and 6). These data clearly map the domain of Tat that interacts with TFIIB to be between amino acid residues 10 and 48, and indicate that the cysteine-rich and core domains are necessary for this interaction.
Mapping of the TFIIB domain interacting with Tat
Several studies have led to the definition of different functional domains in TFIIB. A C-terminal domain contains two direct repeats, which are reminiscent of those present in TBP, and is resistant to digestion by proteases (Barberis et al., 1993 ; Ha et al., 1991 ; Malik et al., 1991 Malik et al., , 1993 Roberts & Green, 1994) . This domain interacts with TBP and permits formation of the DNA.D.B complex (Barberis et al., 1993 ; Hisatake et al., 1993 ; Malik et al., 1993 ; Yamashita et al., 1992) . The N-terminal domain is involved in the P. Veschambre and others P. Veschambre and others Several Tat mutants were produced as GST fusion proteins. These mutations corresponded to : a deletion of the N-terminal nine amino acid residues and of the C terminus from amino acid residue 49 (∆1-9/∆49-86) ; a deletion of the basic domain (∆49-57) ; a deletion of the N-terminal nine amino acid residues and of the basic domain (∆1-9/∆49-57) ; a substitution of cysteine 30 for glycine and a deletion of the basic domain (C30 G/∆49-57) ; a substitution of lysine-41 for glycine and a deletion of the basic domain (K41 G/∆49-57). After purification on glutathione-agarose beads, these various proteins were migrated through a gel and stained with Coomassie Blue. Equal amounts of proteins were coupled to glutathione-agarose beads. Retention of TFIIB protein (produced and labelled with [
35 S]methionine by in vitro translation) on beads coupled to these various Tat mutants was examined. As controls, the experiment was also performed with GST and wild type GST-Tat. An autoradiogram of the gel of the eluted proteins is represented, together with the positions of the bands of a molecular mass marker run in parallel.
interaction with the small subunit of TFIIF . It includes a zinc-finger motif, which is conserved among several species, and which is involved in interaction with regulatory factors (Colgan et al., 1995) .
To map precisely the Tat-binding domain of TFIIB, a series of short internal deletions scanning the entire protein was tested (Fig. 4) . These mutants, constructed by Hisatake et al. (1993) , have been precisely tested for their ability to allow formation of the DNA.D.B. complex, as well as for their ability to function in a basal transcription in vitro assay. These various TFIIB mutants were produced and radioactively labelled by in vitro translation (Fig. 4 A) and their retention on agarose beads coupled to GST-Tat was analysed (Fig. 4 B) . The first mutant (∆11-24) did not markedly affect binding to Tat (Fig. 4 B, lane  1) . This mutation removes half of the zinc-finger motif, which indicates that this structural motif is not important for the interaction with Tat. Deletion ∆27-44 reduced this interaction (Fig. 4 B, lane 2) . This reduction was more pronounced with the following deletions : ∆45-64, ∆67-80 and ∆83-103 (Fig. 4 B,  lanes 3, 4 and 5) . The other mutants, with the notable exception of the ∆148-163 deletion (Fig. 4 B, lane 8) , clearly bound Tat (Fig. 4 B, lanes 6, 7, 9, 10, 11, 12, 13 and 14) . These results show that two domains of TFIIB are involved in the interaction with Tat. The first lies within the N-terminal domain of TFIIB, between amino acid residues 27 and 103. The second is in the first direct repeat of the C-terminal domain, between amino acid residues 148 and 163.
Interaction between Tat and TFIIB intervenes in the activation of the HIV-1 promoter by Tat
Whether Tat and TFIIB actually form a complex in vivo was first examined by performing immunoprecipitation experiments. Tat and TFIIB were coexpressed by transfection in HeLa cells. Immunoprecipitation assays were performed using the 2G8 monoclonal antibody directed against TFIIB, and proteins were analysed by immunoblotting using a polyclonal antibody raised against Tat (Hauber et al., 1987) . This experiment showed that Tat coimmunoprecipitates with TFIIB (Fig. 5, lane 1) . When Tat was overexpressed together with the mutant ∆67-80, a much weaker band was observed (Fig. 5,  lane 2) . As a similar band was observed in the absence of overexpressed TFIIB (Fig. 5, lane 3) , it is probably due to the interaction of Tat with the endogenous TFIIB rather than with the mutant ∆67-80. These data show that Tat binds to TFIIB in a cellular context. 1-3) plus either pSG-TFIIB (lane 1) or pSG-TFIIB ∆67-80 (lane 2). Immunoprecipitations were performed using the 2G8 monoclonal antibody directed against TFIIB (Moncollin et al., 1992) . After separation in a gel, immunoprecipitated proteins were analysed by immunoblotting using a rabbit polyclonal antibody directed against Tat (Hauber et al., 1987) . Arrow, position of signal corresponding to Tat protein.
The results of transfection experiments performed with the GBTat fusion protein supported the notion of a functional interaction between Tat and TFIIB. The role of this interaction was further evaluated in the context of the entire HIV-1 promoter. A reporter construct including the HIV-1 LTR fused to the CAT gene was transfected in HeLa cells, together with vectors expressing Tat and TFIIB (Fig. 6 A) . Elevated concentrations of TFIIB caused a progressive reduction of the Tatinduced activity of the HIV-1 promoter. In order to determine whether the progressive inhibition was related to an interaction with Tat, the effect of a simultaneous increase in the Tat concentration was evaluated. In the absence of overexpressed TFIIB, the activity of the HIV-1 promoter was similar at these different concentrations of Tat (Fig. 6 A, lanes 1-3) . It would appear that Tat, when present in higher concentration, weakened the inhibition exerted by TFIIB (Fig. 6 A, lanes 4 and 6, for instance). For further confirmation that the inhibition exerted by elevated concentrations of TFIIB results from titration of Tat, not of some components of the preinitiation complex, the effect of the overexpression of TFIIB on the activity of the HIV-1 promoter in the absence of Tat was examined. In order to obtain a detectable activity, the amount of reporter plasmid used for transfection was increased. In contrast to what was observed in the presence of Tat, the overexpression of TFIIB led to a moderate increase in the basal activity of the promoter (Fig. 6 B) . The effect of the TFIIB overexpression was also tested with another active viral promoter. Increased intracellular concentrations of TFIIB did not affect the activity of the SV40 early promoter (Fig. 6 C) .
The previous transfection experiments were performed by transfecting reporter plasmids. To eliminate an experimental bias due to the plasmid reporter constructs, the effect exerted by TFIIB overexpression was also tested using a HeLa cell line stably transformed with a construct containing the HIV-1 LTR fused to the lacZ gene (Clavel & Charneau, 1994) . This experimental system mimics the integrated provirus more precisely. Similarly to what was observed with reporter P. Veschambre and others P. Veschambre and others (Emerman et al., 1987 ) (15 ng) was transfected together with various amounts of pSG-TFIIB and pSG-Tat, as indicated. (B) The same experiment was performed with 2 and 4 µg of the pHIV-1 LTR-CAT plasmid and without the Tat expression vector. (C) This experiment was also performed with the pSV2CAT reporter construct (1 µg), which contains the SV40 early promoter fused to the CAT gene (Gorman et al., 1982) . The CAT concentrations were measured and are represented as described in the legend to Fig. 1. plasmids, overexpression of TFIIB inhibited Tat-induced transcription driven by the HIV-1 promoter, and this effect was corrected by an increase in the intracellular concentration of Tat (Fig. 7 A, lanes 1, 2, 3 and 4) . To evaluate further whether Tat interacts with TFIIB in the context of the HIV-1 promoter, experiments were performed with different mutants of TFIIB. Mutants ∆67-80, ∆83-103, ∆148-163 and ∆208-227 were selected for this purpose. The first two weakly bound Tat in vitro (Fig. 4 B, lanes 3 and 4) , but allowed basal transcription (Hisatake et al., 1993) . Mutant ∆148-163 was defective for basal transcription (Hisatake et al., 1993) and also for binding Tat in vitro (Fig. 4 B, lane 8) . Finally, mutant ∆208-227 was defective for basal transcription (Hisatake et al., 1993) , but clearly interacted with Tat in vitro (Fig. 4 B, lane 11) .
Expression of mutant ∆208-227 led to an inhibition which was corrected by an increased amount of Tat (Fig. 7 A, lanes 7  and 8) . Although inactive for formation of the DNA.D.B complex and basal transcription (Hisatake et al., 1993) , this latter mutant therefore gave an effect which was similar to that exerted by wild-type TFIIB (Fig. 7 F, H) . A similar effect was observed with mutant ∆187-206 (data not shown) which is also defective for basal transcription (Hisatake et al., 1993) . In contrast, mutant ∆148-163, which does not bind to Tat, did not exert any effect, whatever the concentration of Tat (Fig.  7 A, lanes 5 and 6 ; Fig. 7 G) . The level of expression of these two mutants in HeLa cells was evaluated by immunoblotting using the 2G8 monoclonal antibody directed against TFIIB (Moncollin et al., 1992) . The signal corresponding to mutants ∆148-163 and ∆208-227 was significantly lower compared to that of wild-type TFIIB (Fig. 7 B) . This indicates that mutants ∆148-163 and ∆208-227 are produced in lower quantities than wild type TFIIB. This poorer expression has already been reported for mutants in the C-terminal domain of TFIIB (Colgan et al., 1995) . It should be noted that only 10 % of the cells are transfected in these experiments as evaluated by immunofluorescence (data not shown). The band corresponding to these mutants (lower band) has about half the intensity of that corresponding to endogenous TFIIB (upper band), which means that these two latter mutants are present at an intracellular concentration approximately five times higher than that of the endogenous factor. That mutant ∆208-227 led to an inhibition similar to that induced by wild-type TFIIB, although that of the former was more weakly produced (Fig.  7 B) , was probably due to better binding of this mutant to Tat compared to wild-type TFIIB (Fig. 4 A, lanes 11 and 15) .
Mutants ∆67-80 and ∆83-103 both inhibited the Tatinduced activity of the HIV-1 promoter. This inhibitory effect was more pronounced than that due to wild-type TFIIB (Fig.  7 C, lanes 3 and 5) . These two mutants allowed formation of the DNA.D.B. complex and basal transcription (Hisatake et al., 1993) , but did not interact with Tat. Expression of these mutants was also analysed by immunoblotting. Considering that the band of wild-type TFIIB was superimposed with that corresponding to the endogenous factor, mutants ∆67-80 and ∆83-103 were produced in similar quantities compared to the wild-type TFIIB (Fig. 7 D) . Given the low percentage of transfected cells, these data indicated that these two mutants CCEA Fig. 7 . Effect of overexpression of TFIIB, either wild type or including mutations ∆67-80, ∆83-103, ∆148-163 and ∆208-227, on the Tat-induced activity of the HIV-1 promoter integrated in the cellular genome. HeLa P4 cells (Clavel & Charneau, 1994) were transfected with pSG-Tat minus and plus 2n5 µg of pSG-TFIIB, pSG-TFIIB ∆148-163, pSG-TFIIB ∆208-227 (A) and pSG-TFIIB ∆67-80, pSG-TFIIB ∆83-103 (B). This experiment was performed with 0n85 and 2n2 µg Tat. The β-galactosidase activity was measured using the β-galactosidase Enzyme Assay System (Promega). The mean of the values obtained for the different points made in duplicate is represented. Expression of the various TFIIB mutants in HeLa cells was analysed. HeLa cells were transfected with vectors expressing TFIIB wild type (B, D, lanes 1), TFIIB ∆148-163 (C, lane 2), TFIIB ∆208-227 (C, lane 3), TFIIB ∆67-80 (D, lane 2) and TFIIB ∆83-103 (D, lane 3). A protein extract was prepared from the transfected cells and analysed by immunoblotting using the 2G8 monoclonal antibody. Upper arrow, position of the signal corresponding to wild-type TFIIB ; lower arrow, that of mutated TFIIB. The 2G8 monoclonal antibody recognizes the second direct repeat of TFIIB and reacts equally against these four TFIIB mutants (data not shown). (E-I) Schematic model of the interaction between Tat and both TBP and TFIIB. This model is represented with one molecule of Tat interacting with TBP and another with TFIIB (Bogerd et al., 1993) . The various situations resulting from overexpression of the TFIIB mutants ∆148-163 (G), ∆208-227 (H), ∆67-80 (I), ∆83-103 (I) are illustrated.
were in high excess with respect to the endogenous TFIIB. This excess probably led to preferential recruitment of these mutants to the transcriptional initiation complex by interaction with other factors. These mutants, which cannot interact with Tat, permitted only a reduced rate of transcription (Fig. 7 I) . In favour of such a model, an increased amount of Tat did not modify this transcription rate (Fig. 7 C, lanes 4 and 6) . Such a negative dominant effect of TFIIB mutants permitting basal transcription, but unable to bind to the transactivator, has already been reported in the case of VP16 from results of in vitro transcription experiments (Roberts et al., 1995) . This inhibitory effect exerted by the ∆67-80 and ∆83-103 mutants demonstrates that the Tat-TFIIB interaction is important in the context of the preinitiation complex forming on the HIV-1 promoter.
To further establish that these inhibitory effects were dependent on Tat, the effect of the overexpression of these TFIIB mutants on the basal activity of the HIV-1 promoter was examined. This was performed by transfecting the pHIV1 LTR-CAT construct in HeLa cells in order to obtain a detectable CCEB P. Veschambre and others P. Veschambre and others basal activity of the promoter. As previously shown, overexpression of TFIIB slightly increased the activity of the promoter (Fig. 8, lanes 1 and 2) . A very similar effect was observed with mutants ∆148-163, ∆68-80 and ∆83-103 (Fig.  8, lanes 3, 5 and 6 ). With mutant ∆208-227 this increase was significantly stronger (Fig. 8, lane 4) . These positive effects are probably related to titration of inhibitory molecules. It is interesting to note that ∆68-80 and ∆83-103, which are likely to enter the preinitiation complex, do not have any inhibitory effect under these conditions. The overexpression of these TFIIB mutants did not affect the activity of the SV40 early promoter (data not shown). These observations clearly show that the inhibitory effects exerted by mutants ∆68-80, ∆83-103 and ∆208-227 are not the consequence of modifications of the basal activity of the promoter, and only occur when Tat transactivates the promoter.
Discussion
Tat/TFIIB protein-protein interaction A specific binding of Tat to TFIIB was observed in vitro. As this interaction was observed using proteins purified from bacteria, it is direct and not mediated by a bridging factor. The cysteine-rich and core domains of Tat, which mediate this interaction, are essential for the activity of this transactivator on the HIV-1 promoter (Green et al., 1989 ; Kuppuswamy et al., 1989) . Two different domains of TFIIB are important for binding to Tat. The first, in the N-terminal domain, is located between amino acid residues 27 and 103. The second important region lies within the first direct repeat of the C-terminal domain, between amino acid residues 148 and 163. From the recent studies of the TFIIB structure, this region corresponds to the loop linking the H2\B1 and H3\C1 helical motifs (Bagby et al., 1995 ; Nikolov et al., 1995) . This prominent hydrophilic region, which is well conserved among several species, represents a possible site of interaction with activators (Bagby et al., 1995 ; Nikolov et al., 1995) .
The Tat binding site in TFIIB is different to those which have been mapped for other transcriptional activators. Binding of the herpes simplex virus acidic activator Vp16 mainly depends on the basic region located at the end of the first direct repeat (Roberts & Green, 1994 ; Roberts et al., 1993) . The N terminus of the human thyroid hormone receptor β also interacts with this region of TFIIB (Baniahmad et al., 1993) . In contrast, the glutamine-rich transcriptional activation domain of fushi tarazu binds to the zinc-finger motif located at the N terminus of TFIIB (Colgan et al., 1995) . That this latter interaction indeed participates in transcriptional activation exerted by this domain of fushi tarazu has been shown by analysis of the inhibitory effect of TFIIB mutants interacting with this activator, but unable to enter the transcriptional initiation complex (Colgan et al., 1993 (Colgan et al., , 1995 . Consistently, the results presented in this report demonstrate an inhibitory effect on the activity of the entire HIV-1 promoter by TFIIB mutants that interact with Tat but are defective for basal transcription. In the case of the fushi tarazu transcriptional activation domain, disrupting the zinc-finger structure in TFIIB by changing histidine-17 to serine abrogates formation of the complex. For Tat, the zinc-finger motif of TFIIB is clearly not essential. Deletion of the N-terminal half of this motif, which completely disrupts this structure, did not affect binding of Tat. Conversely, several mutants of TFIIB possessing this complete structural motif were unable to bind to Tat. The putative basic amphipathic α-helix at the end of the first repeat, which is important for interaction with Vp16 and TBP, is dispensable for the interaction with Tat. These observations indicate that Tat interacts with a specific domain of TFIIB. These data also emphasize that transcriptional activators bind to various regions of TFIIB.
Interaction between Tat and multiple transcription factors
From several studies it appears that Tat interacts with various transcription factors, which bind either to upstream regulatory sequences or to core promoter elements. Sp1 is retained on a column of immobilized Tat (Jeang et al., 1993) . Tat also binds to a factor expressed in neuroglial cells which is part of a complex binding to the κB sites (Taylor et al., 1995) . Concerning the general transcription factors, Tat has been shown to bind to the C-terminal domain of TBP (Kashanchi et al., 1994 ; Veschambre et al., 1995) , as well as to TAFII55 (Chiang & Roeder, 1995) . We show in this report that it also binds to TFIIB. During the completion of our study, it was reported that Tat binds to a factor, TAP, which can interact with TFIIB (Yu et al., 1995 a, b) . It is clear that the binding of Tat to TFIIB studied here does not depend on TAP, as this latter factor interacts with the C-terminal domain of TFIIB . Remarkably, in all these cases the core domain of Tat is essential for the interaction. Thus, it appears that the core domain mediates binding of Tat to seemingly unrelated protein domains. It is possible that this region presents some flexibility, allowing adaptation to the contacted protein.
At present only the interactions of Tat with Sp1 and TBP have been supported by genetic evidence (Kamine & Chinnadurai, 1992 ; Kamine et al., 1993 ; Veschambre et al., 1995) . That the other proteins mentioned functionally interact with Tat in the context of the HIV-1 promoter remains to be evaluated. It is difficult to conceive from a structural point of view that such multiple interactions, which are all mediated by the same ten amino acid domain of Tat, occur simultaneously on a unique Tat molecule. Thus, it is most likely that multiple Tat molecules binding to various factors are present in the transcriptional initiation complex. The possibility exists that the Tat monomers associate. Such a notion has received support from experiments performed using the yeast twohybrid system, which show that Tat interacts with itself (Bogerd et al., 1993) . In such a model the small Tat protein would appear as a molecular glue stabilizing various general transcription factors in the initiation complex.
Dual interaction of Tat with both TFIID and TFIIB
The effect exerted by elevated intracellular concentrations of either TBP or TFIIB is different when assayed with a simplified promoter, corresponding to the HIV-1 TATA box downstream of GAL4 binding sites, than with the entire HIV-1 LTR. In the first case, overexpression of TBP markedly increased transcription in the presence of GBTat. Overexpression of TFIIB has no effect by itself, but leads to a cooperative effect with TBP. In this experimental system it is likely that binding of TBP to the TATA box represents a limiting step, which is overcome by increasing TBP concentration in the presence of Tat. Association of TFIIB with TBP then probably represents a second limiting step, which is facilitated by TFIIB overexpression. It has been shown by in vitro transcription experiments that recruitment of TFIIB is assisted by transcriptional activators (Kim & Roeder, 1994 ; Lin & Green, 1991) . It has also been reported that TFIIB is not tightly associated with the template and is released after initiation (Zawel et al., 1995) . It is likely that Tat, by interacting with this general transcription factor, either maintains it in the complex or causes its rapid reassociation with the HIV-1 promoter.
In the context of the entire HIV-1 promoter, the increase in the concentrations of either TBP (Veschambre et al., 1995) or TFIIB led to progressive suppression of the Tat-induced activity. Thus, in the natural promoter Tat probably does not assist recruitment of both TBP and TFIIB to the promoter. These events are most probably favoured by the cellular transcription factors interacting with the HIV-1 promoter sequences. Hence, the absence of elevated transcriptional activity could be the consequence of a poor interaction between both factors. Such a notion is supported by several studies on TFIIB. Experiments concerning digestion by proteases have shown that this protein is composed of a protease-sensitive N-terminal domain and a protease-resistant C-terminal domain (Barberis et al., 1993 ; Malik et al., 1993 ; Roberts & Green, 1994) . This latter domain, which interacts with TBP, allows formation of the DNA.D.B complex. The Nterminal domain has an inhibitory effect on this function (Malik et al., 1993 ; Roberts & Green, 1994) . This is probably related to the property of the N-terminal domain to bind to the Cterminal domain (Roberts & Green, 1994) . It has been shown that Vp16 impairs this inhibitory effect by interacting with the C-terminal domain of TFIIB (Roberts & Green, 1994) . It is possible that Tat, by interacting with both TBP and TFIIB, favours the association of the two factors, allowing by induction of conformational changes, the transition of the DNA.D.B. complex to an active state.
In conclusion, Tat appears to act on transcriptional initiation by establishing multiple interactions. The general transcription factors TBP and TFIIB appear to be two important targets. As shown by the results of transient expression studies, the interactions between Tat and these two proteins play a functional role in the living cell. In addition to its activity at the level of the transcriptional initiation complex, Tat also has an effect on elongation stability which remains to be elucidated at the molecular level.
